Cellectar Biosciences Inc
NASDAQ:CLRB

Watchlist Manager
Cellectar Biosciences Inc Logo
Cellectar Biosciences Inc
NASDAQ:CLRB
Watchlist
Price: 3.59 USD 4.06% Market Closed
Market Cap: 11.5m USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

CLRB doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CLRB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLRB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5
Median 5Y
-6.4
Industry
24.4
Forward
-0.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-8.2
Industry
21.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-8
Industry
23.2
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
88
vs Industry
57
Median 3Y
9.4
Median 5Y
15.2
Industry
3.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
0
vs Industry
31
Median 3Y
-4.4
Median 5Y
-6.5
Industry
6.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
0
vs Industry
29
Median 3Y
-4.4
Median 5Y
-6.4
Industry
7
Forward
-0
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
0
vs Industry
33
Median 3Y
-5
Median 5Y
-7.5
Industry
7.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
0
vs Industry
29
Median 3Y
-4.9
Median 5Y
-7.3
Industry
6.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
0
vs Industry
56
Median 3Y
-33.4
Median 5Y
-56.6
Industry
5.5
More Details

Multiples Across Competitors

CLRB Competitors Multiples
Cellectar Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cellectar Biosciences Inc
NASDAQ:CLRB
11.5m USD 0 -0.4 -0 -0
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 198 755.5 -162 541.6 -197 377.4 -195 125
US
Abbvie Inc
NYSE:ABBV
402.4B USD 6.7 171.4 16.6 23.5
US
Amgen Inc
NASDAQ:AMGN
185.9B USD 5.2 26.5 19 19
US
Gilead Sciences Inc
NASDAQ:GILD
156.3B USD 5.4 19.3 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.1B USD 9.4 30 21.9 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 060 -525.7 -572.4 -557.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.2B USD 5.8 17.9 17.1 19.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.1B USD 24 -185.2 -463 -317.8
AU
CSL Ltd
ASX:CSL
90.2B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
47.9B EUR 15.4 36.2 62.8 64.5
P/S Multiple
Revenue Growth P/S to Growth
US
Cellectar Biosciences Inc
NASDAQ:CLRB
Average P/S: 3 420 089.1
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 198 755.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
10%
0.9
US
E
Epizyme Inc
F:EPE
2 060
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
5%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24
44%
0.5
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.4
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Cellectar Biosciences Inc
NASDAQ:CLRB
Average P/E: 45.9
Negative Multiple: -0.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 541.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.5
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.3
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
8%
2.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -185.2 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
36.2
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cellectar Biosciences Inc
NASDAQ:CLRB
Average EV/EBITDA: 23.4
Negative Multiple: -0 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
19
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -463 N/A N/A
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
62.8
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cellectar Biosciences Inc
NASDAQ:CLRB
Average EV/EBIT: 25.5
Negative Multiple: -0 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 125 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
19
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
12%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -317.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
64.5
N/A N/A

See Also

Summary
CLRB intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLRB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLRB stock valuation using valuation multiples.
Wall Street Estimates
CLRB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLRB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 299,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.